BELLUS Health Inc. (BLU)
BELLUS Health Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Laval, QC, CA. The stock last traded at $14.74, up 0.03% on the session, giving a market capitalisation of $1.87B. On trailing twelve-month figures it carries a trailing P/E of -22.34, a net margin of -475500.0%. Its beta of -0.28 implies it has historically moved less than the broad market.
BELLUS Health Inc. is a clinical-stage biopharmaceutical company headquartered in Laval, Canada, and founded in 1993. The firm focuses on developing therapeutic solutions for refractory chronic cough (RCC) and other related cough hypersensitivity conditions. Its leading product candidate, BLU-5937, an antagonist designed to block the P2X3 receptor, is currently progressing through Phase II clinical trials for the treatment of both RCC and chronic pruritus.
BELLUS Health Inc. is most often compared with the following Healthcare names: